Use of Simvastatin to Inhibit Advanced Prostate Cancer Formation in the TRAMP Mouse Model of Prostate Cancer

2013 ◽  
Author(s):  
Sara K. Drenkhahn
Cancers ◽  
2011 ◽  
Vol 3 (3) ◽  
pp. 3353-3369 ◽  
Author(s):  
Xiaohua Gao ◽  
Dorrah Deeb ◽  
Yongbo Liu ◽  
Ali S. Arbab ◽  
George W. Divine ◽  
...  

Endocrinology ◽  
2019 ◽  
Vol 160 (8) ◽  
pp. 1786-1796
Author(s):  
Henry H Moon ◽  
Katrina L Clines ◽  
Mark A Cooks ◽  
Charlotte A Cialek ◽  
Marian A Esvelt ◽  
...  

Abstract Bone metastasis is a painful complication of advanced prostate cancer. Endothelin-1 is a tumor-secreted factor that plays a central role in osteoblast activation and the osteosclerotic response of prostate cancer metastatic to bone. Antagonists that block the activation of the endothelin A receptor (ETAR), located on osteoblasts, reduce osteoblastic bone lesions in animal models of bone metastasis. However, ETAR antagonists demonstrated limited efficacy in clinical trials of men with advanced prostate cancer who also received standard androgen deprivation therapy (ADT). Previous data from our group suggested that, in a mouse model, ETAR antagonists might only be efficacious when androgen signaling in the osteoblast is lowered beyond the ability of standard ADT. This notion was tested in a mouse model of prostate cancer bone metastasis. Castrated and sham-operated male athymic nude mice underwent intracardiac inoculation of the ARCaPM castration-resistant prostate cancer cell line. The mice were then treated with either the ETAR antagonist zibotentan or a vehicle control to generate four experimental groups: vehicle+sham (Veh+Sham), vehicle+castrate (Veh+Castr), zibotentan+sham (Zibo+Sham), and zibotentan+castrate (Zibo+Castr). The mice were monitored radiographically for the development of skeletal lesions. The Zibo+Castr group had significantly longer survival and a single incidental lesion. Mice in the Zibo+Sham group had the shortest survival and the largest number of skeletal lesions. Survival and skeletal lesions of the Veh+Sham and Veh+Castr groups were intermediate compared with the zibotentan-treated groups. We report a complex interaction between ETAR and androgen signaling, whereby ETAR blockade was most efficacious when combined with complete androgen deprivation.


2013 ◽  
Vol 180 (4) ◽  
pp. 376 ◽  
Author(s):  
M. D. Lawrence ◽  
R. J. Ormsby ◽  
B. J. Blyth ◽  
E. Bezak ◽  
G. England ◽  
...  

2013 ◽  
Vol 110 (37) ◽  
pp. E3506-E3515 ◽  
Author(s):  
A. Aytes ◽  
A. Mitrofanova ◽  
C. W. Kinkade ◽  
C. Lefebvre ◽  
M. Lei ◽  
...  

Oncotarget ◽  
2018 ◽  
Vol 9 (14) ◽  
pp. 11752-11766 ◽  
Author(s):  
Caroline K. Søgaard ◽  
Siver A. Moestue ◽  
Morten B. Rye ◽  
Jana Kim ◽  
Anala Nepal ◽  
...  

2012 ◽  
Vol 2 (1) ◽  
Author(s):  
Kim Moran-Jones ◽  
Anita Ledger ◽  
Matthew J. Naylor

2010 ◽  
Vol 13 (1) ◽  
pp. 70-76 ◽  
Author(s):  
Ananda S. Prasad ◽  
Hasan Mukhtar ◽  
Frances W.J. Beck ◽  
Vaqar M. Adhami ◽  
Imtiaz A. Siddiqui ◽  
...  

2013 ◽  
Vol 19 (1) ◽  
pp. 409-416 ◽  
Author(s):  
Paloma Olvera-Caltzontzin ◽  
Guadalupe Delgado ◽  
Carmen Aceves ◽  
Brenda Anguiano

2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Nancy Moran ◽  
Jennifer M Thomas-Ahner ◽  
Hsueh-Li Tan ◽  
Ceasar Silva ◽  
Noor Hason ◽  
...  

Abstract Objectives Epidemiologic evidence suggests consuming tomato and lycopene are associated with a reduced risk of advanced and lethal prostate cancer. Prior studies of prostate cancer prevention in the TRAMP mouse model indicate that lifelong tomato- or lycopene-feeding reduce incidence of early carcinoma by up to 70%, and this effect is dependent on the expression of Bco2 (beta-carotene oxygenase 2, a carotenoid metabolic enzyme). We hypothesize that gene expression patterns will reveal the mechanisms by which these diets act to disrupt early carcinogenesis. Methods To define the early transcriptional responses in the dorsolateral mouse prostate, TRAMP and wild-type littermate mice were crossed with Bco2+/+ or Bco2−/− mice (C57/Bl6 background). All 4 crosses were fed either control, lycopene, or 10% tomato powder diets from weaning at 3 weeks until 8 weeks. Expression of 84 genes was measured by a prostate cancer-focused PCR array (n = 5/group). Protein expression was measured by Western blotting (n = 4/group) and serum carotenoids by HPLC (n = 3–4/group). Statistical effects of TRAMP and Bco2 genotypes and diet treatment on final body mass (n = 6/group), serum lycopene, and gene expression were analyzed by ANOVA (alpha = 0.05). Results Body masses were not influenced by genotypes or diets. Serum lycopene concentrations were subject to a Bco2 genotype effect (P = 0.004), with greater lycopene being present in Bco2−/− mice than Bco2 +/+mice, but did not differ by TRAMP genotype nor between lycopene vs tomato diets. The TRAMP genotype influenced the expression of 49 genes, diet impacted expression of 11 genes, and Bco2 genotype influenced expression of 2 genes. Expression of 4 genes, Apc, Mto1, Nfkb1, and Rbm39, were subject to a significant Bco2 x diet interaction. Expression of 5 genes related to lipid metabolism, Fasn, Acaca, Srebf1, Hmgcr, and Ptgs1, were impacted by a diet effect. Conclusions Semi-targeted analyses suggest tomato and lycopene may affect lipid metabolism in early carcinogenesis. Future studies may elaborate upon specific pathways modulated by tomato and lycopene in early prostate carcinogenesis. Funding Sources NIH/National Cancer Institute, NIH/National Center for Complementary and Integrative Health, USDA/Agricultural Research Service.


Sign in / Sign up

Export Citation Format

Share Document